Wearable Emotion Prosthetics for Post Traumatic Stress Disorder (EP-PTSD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03529981 |
Recruitment Status :
Recruiting
First Posted : May 21, 2018
Last Update Posted : January 13, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Involuntary stress reactions including hyper-reactivity and dissociation are key diagnostic features of many psychiatric disorders, are difficult to treat, and predict poor outcomes in conventional and neurobehavioral interventions. Here, we evaluate the extent to which a novel intervention, Tuned Vibroacoustic Stimulation (TVS), capitalizing on a preserved neurocircuitry for sympathetic and parasympathetic system activity can be used to modify arousal responses, overriding otherwise prepotent negative stress reactions.
PTSD has been characterized by dysregulated responses to stress as a result of severe acute or chronic trauma resulting in significantly impaired functioning, quality of life, and morbidity/mortality. Physiologically, PTSD severity has been associated with elevated sympathetic tone and low heart rate variability suggesting that parasympathetic tone is suppressed. Lower heart rate variability specifically, as a measure of parasympathetic tone, is closely associated with impaired performance and resilience. In our first study (in review), we showed that in some individuals, TVS is associated with increased heart rate variability and performance under stress along with reduced subjective stress. These results suggest that TVS could provide some therapeutic benefit in PTSD.
N=100 individuals with mild-moderate PTSD (as assessed by PCL-5/CAP5), at least half of which are military Veterans, will be assessed physiologically during active interventions. Mechanisms of attentional focus on cognitive and emotional stimuli will be assessed. Participants will also have a real-world intervention to determine if TVS helps alleviate stress, symptoms, and medication burden in the real world when stress has been identified. Success will suggest a new intervention pathway for a traditionally treatment-resistant dimension of psychopathology.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Health Behavior | Other: Tuned Vibroacoustic Stimulation (TVS) Other: no active intervention | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Intervention Model Description: | randomized, controlled factorial within subject design |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Wearable Emotion Prosthetics for Post Traumatic Stress Disorder |
Actual Study Start Date : | April 9, 2018 |
Estimated Primary Completion Date : | December 18, 2022 |
Estimated Study Completion Date : | December 18, 2022 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Stress incidents without TVS
a fraction of physiological detected stress incidents will not trigger TVS
|
Other: no active intervention
No intervention will be administered |
Experimental: TVS in response to participant initiation or stress detection
The majority of detected stress incidents will trigger TVS. Participants can also trigger TVS voluntarily
|
Other: Tuned Vibroacoustic Stimulation (TVS)
TVS is an exteroceptive cue that may reduce subjective and physiological indicators of stress and increase behavioral performance |
- Change in symptom ratings from pre- to post- [ Time Frame: Change in symptom ratings over the approximately two weeks of the acute intervention (pre- to post- assessment) ]Subjective affect / symptom ratings will be obtained daily. Spline fitting will be used to create a smoothed estimate of trajectory, the beginning and end points of which will be compared.
- Change in resting Heart Rate Variability (HRV) from pre- to post- [ Time Frame: HRV will be measured during the entire study which is two weeks ]HRV, an index of parasympathetic reactivity, will be obtained throughout the day during the study. Increased HRV indicates increased parasympathetic reactivity, which suggests an increased physiological indicator of emotion regulation. Spline fitting will be used to create a smoothed estimate of trajectory, the beginning and end points of which will be compared.
- Change in Heart Rate Variability (HRV) during information processing tasks (composite) [ Time Frame: HRV will be measured during the approximately 1 hour of information processing tasks, which will be administered approximately 2 weeks apart, at the pre- and post- intervention assessment visits. ]HRV, an index of parasympathetic reactivity, will be obtained during laboratory information processing tasks (paced auditory serial attention, emotional picture viewing). Increased HRV indicates increased parasympathetic reactivity, which suggests an increased physiological indicator of emotion regulation.
- Galvanic skin response (GSR) during information processing tasks (composite) [ Time Frame: GSR will be measured during the approximately 1 hour of information processing tasks, which will be administered approximately 2 weeks apart, at the pre- and post- intervention assessment visits. ]GSR, index of sympathetic reactivity, will be obtained during lab tasks before and after the intervention. Decreased GSR indicates decreased sympathetic reactivity, which suggests an increased physiological indicator of emotion regulation.
- prefrontal gamma band EEG during information processing tasks (composite) [ Time Frame: EEG will be measured during the approximately 1 hour of information processing tasks, which will be administered approximately 2 weeks apart, at the pre- and post- intervention assessment visits. ]prefrontal gamma band EEG will be obtained during lab information processing tasks. Increased prefrontal gamma band EEG suggests an increased physiological indicator of emotion regulation.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 58 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male/female who are 18 - 58 years of age
- For PTSD participants, must meet current DSM-V criteria for PTSD based on the PCL-5 (Score > 33) and MINI PTSD Scale (administered in lab).
- If taking psychoactive medications, must be on a stable regimen for 3 weeks or more.
- Must have a functioning smartphone with Apple iOS or Android
Exclusion Criteria:
- Refusal or inability to provide informed consent
- Current suicidal or homicidal ideation with intent and/or plan that, in the judgment of the investigator, should be the focus of treatment.
- Current or recent (within the last 8 weeks) physically aggressive behavior.
- Meets current DSM-V criteria for substance dependence ((serious substance use in DSM-V parlance, not in remission) except nicotine and caffeine), traumatic brain injury, bipolar affective disorder, schizophrenia or any psychotic disorder.
- Has unstable or serious medical illness, including history of stroke, epileptic disorder, or unstable cardiac disease, that would interfere with participation in treatment.
- Taking medications that could affect thinking which must be taken on the day of testing, or dependence on psychoactive drugs (prescription or non-prescription) that could affect thinking. That is, participants need to be able to think clearly to complete the proposed information processing tasks. And they need to be able to learn to be able to make use of the intervention. Examples of drugs which could affect performance on cognitive tasks or the administered physiological measures include beta-blockers, benzodiazepines, antipsychotics, stimulants (except for treatment of ADD/ADHD), narcotics, and anti--Parkinsonian drugs.
- Severe cognitive impairment or severe trauma
- Unable to comprehend or communicate in English, and unable to complete questionnaires written in English.
- Having any eye problems or difficulties in corrected vision or hearing, including poor color vision
- Having a North American Adult Reading Test (NAART) equivalent FSIQ < 85
- Severe or poorly controlled concurrent medical disorders or require medication that could cause negative thinking
Specific Exclusions for acoustic vibration include:
-- Any electrical implant (pacemaker, vagus nerve stimulator, etc).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03529981
Contact: Lisa Stupar | 412-980-5342 | StuparLM@upmc.edu |
United States, Pennsylvania | |
Western Psychiatric Institute and Clinic | Recruiting |
Pittsburgh, Pennsylvania, United States, 15213 | |
Contact: Lisa Stupar 412-980-5342 StuparLM@upmc.edu | |
Contact: Marlee Pyzewski 412-8643515 pyzewskiml@upmc.edu | |
Principal Investigator: Greg Siegle, PhD | |
Sub-Investigator: Shan Gao, MD, PhD | |
Sub-Investigator: David Rabin, MD, PhD |
Principal Investigator: | Greg Siegle, MD | Western Psychiatric Institute and Clinic |
Documents provided by Greg Siegle, University of Pittsburgh:
Other Publications:
Responsible Party: | Greg Siegle, Associate Professor, University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT03529981 |
Other Study ID Numbers: |
PRO17110107 |
First Posted: | May 21, 2018 Key Record Dates |
Last Update Posted: | January 13, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Following publication of primary results, individual anonymized data on primary outcome measures will be made available to other researchers. Before publication, primary outcome measures will be shared in negotiation with a proposed analysis plan from qualified investigators. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Time Frame: | Following publication - available to all. Before publication - upon negotiation with qualified investigators |
Access Criteria: | Before publication - available in negotiation with Greg Siegle (gsiegle@pitt.edu). After publication the location of a data repository will be listed |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
PTSD |
Stress Disorders, Traumatic Stress Disorders, Post-Traumatic Trauma and Stressor Related Disorders Mental Disorders |